注射用醋酸奥曲肽微球体内外释放度分析

目的： 研究注射用醋酸奥曲肽微球体外释放度加速试验方法，并探讨与体内释放的相关性，为该制剂的有效性评价研究提供参考。方法： 分别采用转瓶法和流池法考察了温度、pH、转速、流速、样品池的种类、膜的排列方式、玻璃珠以及加样方式等影响因素，建立了体外加速释放在温度37℃、片剂池（22.6 mm）、流速16 mL·min^-1和pH 10.0缓冲液中进行的流池法，并与在温度37℃、转速6 r·min^-1和pH 10.0缓冲液中进行的转瓶法进行对比。结果： 注射用醋酸奥曲肽微球在流池法中的释放均快于转瓶法中的释放；且2种制剂样品不同方法测定结果趋势一致，制剂A释放快于制剂B；对流池法体外加速释放-体内释放进行线性回归，制剂A和B相关系数r分别为0.998 2、0.960 9。结论： 采用流池法测定的体外加速释放快于转瓶法，且与体内释放具有良好的相关性（r>0.9），为评价奥曲肽微球制剂的体内外释放提供参考。

Objective: To study the method of accelerated release of octreotide acetate microspheres for injection in vitro,and to establish the correlation between in vivo and in vitro. Methods: The rotating-bottle method and the flow-through cell method were established. Rotational speed,flow velocity,temperature,pH value,sample pool of species,the arrangement of membrane,glass bead and influence factors such as the way for the accelerated release in vitro was investigated,and the flow-through cell methodwith the temperature of 37℃,tablet cell (22.6 mm),speed 16 mL·min^-1 and pH 10.0 buffer,and the rotating-bottle method with the temperature of 37℃,of 6 r·min^-1 and pH 10.0 bufferwas compared. The concentration of octreotide in rat plasma was determined by LC-MS method. Results: The release rates of octreotide acetate microspheres for injection with the flow-through cell method were faster than that with the rotating-bottle method. The results of the two methods showed the same trend,indicating that the release of brand A was faster than that of brand B. The correlation coefficient r form the linear regression analysis of the correlation between in vitro accelerated release and in vivo release by the flow-through cell method was 0.998 2 and 0.960 9 for brand A and brand B,respectively. Conclusion: The accelerated in vitro release measured with the flow-through cell method is faster than that by the rotating-bottle method,and has a good correlation with the in vivo release (r>0.9). The method could be a reference for the evaluation of the in vivo and in vitro release of octreotide acetate microspheres for injection.

[1] FDA,Label[EB/OL].[2019].U.S.:https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021008s043lbl.pdf
[2] BODMER D,FONG JW,KISSEL T,et al.Sustained release formulation of water soluble peptides:United States,5538739[P].Jul.23,1996
[3] OKADA H,One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate[J].Adv Drug Del Rev,1997,28(1):43
[4] CARDOT JM,TOMIC I.In vitro in vivo correlation basis and application to slow release injectable formulation[J].Farmacia,2015,214:94
[5] TENG W,CHUN Z,WEI Z,et al.Modification of three-phase drug release mode of octreotide plga microspheres by microsphere-gel composite system[J].AAPS Pharm Sci Tech,2019(20):228
[6] TOMIC I,VIDIS-MILLWARD A,MUELLER-ZSIGMONDY M,et al.Setting accelerated dissolution test for PLGA microspheres containing peptide,investigation of critical parameters affecting drug release rate and mechanism[J].Internat J Pharm,2016,505(1-2):42
[7] SHEN J,BURGESS DJ.Accelerated in-vitro release testing methods for extend-edrelease parenteral dosage forms[J].J Pharm Pharmacol,2012,64(7):986
[8] D'SOUZA SS,FARAJ JA,DELUCA PP.A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres[J].Aaps Pharm Sci Tech,2005,6(4):E553
[9] ZOLNIK BS,LEARY PE,BURGESS DJ.Elevated temperature accelerated release testing of PLGA microspheres[J].J Controlled Rel,2006,112(3),293
[10] 彭芳,周凤梅,刘万卉.注射用缓释微球的体外释放度研究[J].齐鲁药事,2011,30(5):285 PENG F,ZHOU FM,LIU WH.Study on release in vitro of sustained-release microspheres for injection[J].Qilu Pharm Aff,2011,30(5):285
[11] 梁苑英竹,林晓鸣,刘万卉,等.肽类微球注射剂释放度实验评价研究进展[J].中国新药杂志,2017,26(24):2918 LIANG YYZ,LIN XM,LIU WH,et al.Evaluation methods of in vitro release rate of peptide microsphere injections:a review[J].Chin J New Drugs,2017,26(24):2918
[12] ZOLNIK BS,BURGESS DJ.Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres[J].Controlled Rel,2008,127(2):137
[13] USP 41-NF 36[S].2018:6459
[14] FDA.Department of health and human services food and drug FDA-recommended dissolution methods[EB/OL].[2017-7-20].[2017-10-08].http://www.accessdata.fda.gov/scripts/cder/dissolution/
[15] 王磊,沙春洁,余飞,等.醋酸奥曲肽缓释微球在大鼠体内的药动学与药效指标评价研究[J].中国新药杂志,2019,28(11):1318. WANG L,SHA CJ,YU F,et al.Evaluation of pharmacokinetics and pharmacodynamic indicators of octreotide acetate sustained release microspheres in rats[J].Chin J New Drugs,2019,28(11):1318
[16] 符旭东,高永良.缓释微球的释放度试验及体内外相关性研究进展[J].中国新药杂志,2003,12(8):608 FU XD,GAO YL.Test for in vitro release rate of microspheres and correlation of its in vivo-in vitro[J].Chin J New Drugs,2003,12(8):608
[17] D'SOUZA S,FARAJ JA,GIOVAGNOLI S,et al.IVIVC from long acting olanzapine microspheres[J].Internat J Biomater,2014,2014:407065